#1 Clinical Trials Search in Europe

Metreleptin

Metreleptin, a recombinant human leptin analog, is being studied in various clinical trials for its potential in treating lipodystrophy and related metabolic complications. These trials aim to evaluate the safety, efficacy, and long-term effects of metreleptin in patients with different forms of lipodystrophy, including generalized and partial lipodystrophy. The studies focus on improvements in metabolic parameters, body composition, and quality of life for patients with these rare conditions.

Table of Contents

What is Metreleptin?

Metreleptin, also known by its brand name MyaLept, is a medication that serves as a synthetic version of the human hormone leptin[1]. Leptin is naturally produced by fat cells in our body and plays a crucial role in regulating energy balance and various physiological functions[2]. Metreleptin is designed to mimic the effects of natural leptin in patients who have a deficiency of this important hormone.

Specifically, metreleptin is a recombinant analog of human leptin. This means it’s a laboratory-created version that’s very similar to the leptin our bodies produce naturally. It’s a 147-amino acid polypeptide (a chain of amino acids) that differs from human leptin by having one additional amino acid, methionine, at one end of the molecule[3].

What Conditions Does Metreleptin Treat?

Metreleptin is primarily used to treat rare conditions associated with leptin deficiency. These include:

  • Generalized Lipodystrophy (GL): This is a rare condition where the body is unable to produce and maintain healthy fat tissue. It can be congenital (present from birth) or acquired later in life[4].
  • Partial Lipodystrophy (PL): Similar to GL, but affects only certain parts of the body[5].
  • Familial Partial Lipodystrophy (FPLD): A genetic form of partial lipodystrophy[6].
  • Congenital Leptin Deficiency (CLD): An extremely rare genetic condition where the body doesn’t produce leptin[2].

These conditions often lead to complications such as severe insulin resistance (which can cause diabetes), high levels of triglycerides in the blood (hypertriglyceridemia), and fatty liver disease[1].

How Does Metreleptin Work?

Metreleptin works by replacing the missing leptin in patients with leptin deficiency. Leptin plays several important roles in the body:

  • It signals to the brain about the body’s energy storage, helping to regulate appetite and metabolism.
  • It helps in regulating blood sugar levels and fat metabolism.
  • It influences various other physiological processes, including immune function and reproductive health[2].

By replacing the missing leptin, metreleptin helps to restore these important functions in patients with leptin deficiency[1].

How is Metreleptin Administered?

Metreleptin is administered as a daily subcutaneous injection. This means it’s injected just under the skin. The medication comes as a powder that needs to be mixed with sterile water before injection[7]. The dosage is typically based on the patient’s body weight and may be adjusted over time based on the patient’s response to the treatment[8].

Effectiveness of Metreleptin

Clinical trials have shown that metreleptin can be effective in treating the complications associated with leptin deficiency. Some of the reported benefits include:

  • Improved blood sugar control: Many patients see a reduction in their HbA1c levels, which is a measure of long-term blood sugar control[5].
  • Reduced triglyceride levels: Metreleptin has been shown to significantly lower triglyceride levels in the blood[5].
  • Decreased liver fat: Some studies have observed reductions in liver volume and improvements in fatty liver disease[9].
  • Weight loss: In patients with congenital leptin deficiency, metreleptin can lead to significant weight loss by reducing hunger and food intake[2].

Safety and Side Effects

Like all medications, metreleptin can cause side effects. Common side effects may include:

  • Reactions at the injection site, such as redness or itching
  • Headache
  • Weight loss
  • Abdominal pain

More serious side effects, though less common, can include:

  • Hypoglycemia (low blood sugar)
  • Pancreatitis (inflammation of the pancreas)
  • T-cell lymphoma (a type of blood cancer)
  • Autoimmune disorders

Ongoing safety studies are monitoring these and other potential risks[4][8]. It’s important for patients to discuss all potential risks and benefits with their healthcare provider.

Ongoing Research and Future Directions

Research on metreleptin is ongoing, with several clinical trials currently in progress. These studies aim to:

  • Further evaluate the long-term safety and efficacy of metreleptin in various forms of lipodystrophy[6].
  • Investigate its use in children under 6 years of age with generalized lipodystrophy[9].
  • Explore its potential in treating other conditions, such as multiple symmetric lipomatosis (a condition characterized by multiple fatty tumors)[7].
  • Better understand the immunogenicity (ability to provoke an immune response) of metreleptin[8].

These ongoing studies will help to further refine the use of metreleptin and potentially expand its applications in treating leptin-related disorders.

Aspect Details
Drug Name Metreleptin (MyaLept)
Primary Conditions Studied Generalized Lipodystrophy, Partial Lipodystrophy, Familial Partial Lipodystrophy
Administration Method Daily subcutaneous injection
Key Outcome Measures Changes in HbA1c, triglyceride levels, insulin sensitivity, body composition, liver volume
Study Durations Ranging from 12 months to over 5 years
Safety Assessments Monitoring of adverse events, immunogenicity, and long-term safety profiles
Additional Investigations Effects on sleep architecture, cognitive function, quality of life, and physiological parameters in specific patient populations

FAQ

  • What is Metreleptin? Metreleptin is a recombinant human leptin analog that is used as a replacement therapy to treat complications of leptin deficiency. It is designed to mimic the effects of naturally occurring leptin, which plays a crucial role in regulating energy homeostasis and metabolic function.
  • What conditions is Metreleptin being studied for? Metreleptin is being studied primarily for various forms of lipodystrophy, including generalized lipodystrophy, partial lipodystrophy, and familial partial lipodystrophy. It is also being investigated for its potential benefits in multiple symmetric lipomatosis (MSL) and congenital leptin deficiency.
  • What are the main goals of the Metreleptin clinical trials? The main goals of these trials are to evaluate the safety, efficacy, and long-term effects of Metreleptin treatment. Researchers are particularly interested in its impact on metabolic parameters such as glycated hemoglobin (HbA1c) levels, triglyceride levels, and insulin sensitivity. They also aim to assess changes in body composition, liver volume, and quality of life for patients.
  • How is Metreleptin administered in these trials? Metreleptin is typically administered as a daily subcutaneous injection. The dosage may vary depending on the patient's weight and specific condition, as outlined in the prescribing information for each trial.
  • What are some of the potential benefits being studied? Potential benefits being studied include improvements in glucose control, reduction in triglyceride levels, changes in body composition, reduction in liver volume, and overall improvements in metabolic health. Some trials are also looking at the drug's impact on quality of life, cognitive function, and other physiological parameters affected by leptin deficiency.

Ongoing Clinical Trials on Metreleptin

  • Study on the Effects of Metreleptin for Patients with Partial Lipodystrophy

    Recruiting

    3 1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy

  • Study on Metreleptin for Patients with Partial Lipodystrophy

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium The Netherlands Poland Spain

  • Study on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy

Glossary

  • Lipodystrophy: A group of disorders characterized by the loss of body fat, which can be generalized (affecting the whole body) or partial (affecting specific areas of the body).
  • Metreleptin: A recombinant analog of human leptin used as a replacement therapy to treat complications of leptin deficiency in patients with lipodystrophy.
  • Leptin: A hormone primarily produced by fat cells that plays a key role in regulating energy balance and body weight.
  • Glycated Hemoglobin (HbA1c): A measure of average blood sugar levels over the past 2-3 months, used to diagnose and monitor diabetes.
  • Triglycerides: A type of fat (lipid) found in the blood, often used as a marker of metabolic health.
  • Insulin Sensitivity: The body's responsiveness to insulin, a hormone that regulates blood sugar levels.
  • Hepatic Steatosis: Accumulation of fat in the liver, also known as fatty liver disease.
  • Hypertriglyceridemia: A condition characterized by high levels of triglycerides in the blood.
  • Familial Partial Lipodystrophy (FPLD): A genetic form of lipodystrophy where fat loss occurs in specific areas of the body.
  • Generalized Lipodystrophy: A form of lipodystrophy characterized by near-total loss of body fat.
  • Multiple Symmetric Lipomatosis (MSL): A rare condition characterized by the growth of fatty masses in various parts of the body.
  • Congenital Leptin Deficiency: A rare genetic disorder characterized by a complete lack of leptin production from birth.

References

  1. https://clinicaltrials.gov/study/NCT02654977
  2. https://clinicaltrials.gov/study/NCT04063488
  3. https://clinicaltrials.gov/study/NCT02404896
  4. https://clinicaltrials.gov/study/NCT02325674
  5. https://clinicaltrials.eu/trial/study-on-the-effects-of-metreleptin-for-patients-with-partial-lipodystrophy/
  6. https://clinicaltrials.gov/study/NCT06679270
  7. https://clinicaltrials.gov/study/NCT05351164
  8. https://clinicaltrials.gov/study/NCT04026178
  9. https://clinicaltrials.eu/trial/study-on-metreleptin-for-children-under-6-with-generalized-lipodystrophy-and-related-diabetes-or-high-triglycerides/